ClinicalThought

Share

Program Content

Activities

  • OC: 1st-Line Maintenance Niraparib
    My Perspective on the Recent Approval of Niraparib as First-line Maintenance Therapy in Ovarian Cancer and the Clinical Implications
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 11, 2021

    Expires: January 10, 2022

Faculty

cover img faculity

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

GlaxoSmithKline